A novel small molecule inhibitor of human Drp1

Sci Rep. 2022 Dec 13;12(1):21531. doi: 10.1038/s41598-022-25464-z.

Abstract

Mitochondrial dynamin-related protein 1 (Drp1) is a large GTPase regulator of mitochondrial dynamics and is known to play an important role in numerous pathophysiological processes. Despite being the most widely used Drp1 inhibitor, the specificity of Mdivi-1 towards human Drp1 has not been definitively proven and there have been numerous issues reported with its use including off-target effects. In our hands Mdivi-1 showed varying binding affinities toward human Drp1, potentially impacted by compound aggregation. Herein, we sought to identify a novel small molecule inhibitor of Drp1. From an initial virtual screening, we identified DRP1i27 as a compound which directly bound to the human isoform 3 of Drp1 via surface plasmon resonance and microscale thermophoresis. Importantly, DRP1i27 was found to have a dose-dependent increase in the cellular networks of fused mitochondria but had no effect in Drp1 knock-out cells. Further analogues of this compound were identified and screened, though none displayed greater affinity to human Drp1 isoform 3 than DRP1i27. To date, this is the first small molecule inhibitor shown to directly bind to human Drp1.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Dynamins* / antagonists & inhibitors
  • GTP Phosphohydrolases / metabolism
  • Humans
  • Mitochondrial Dynamics
  • Quinazolinones* / pharmacology

Substances

  • Dynamins
  • GTP Phosphohydrolases
  • 3-(2,4-dichloro-5-methoxyphenyl)-2-sulfanyl-4(3H)-quinazolinone
  • Quinazolinones
  • DNM1L protein, human